herombopag + cyclosporine A

Herombopag + cyclosporine A is a combination therapy consisting of herombopag, a thrombopoietin receptor agonist, and cyclosporine A, an immunosuppressive agent. This combination is being investigated for the treatment of severe aplastic anemia and other hematologic disorders. Herombopag stimulates platelet production by activating the thrombopoietin receptor (MPL), while cyclosporine A suppresses immune-mediated destruction of hematopoietic cells by inhibiting calcineurin in T cells, thereby reducing cytokine production such as interleukin-2. The rationale for combining these agents is to synergistically enhance hematopoiesis through complementary mechanisms—herombopag promoting platelet recovery and cyclosporine A dampening immune-mediated marrow suppression[5][6][7][8].

Other names

CsA + herombopagcyclosporine A + herombopag